Otsuka Pharmaceutical has entered a definitive merger agreement to fully acquire Jnana Therapeutics for USD 800 million with an additional payment of up to USD 325 million dependent on development and regulatory milestones. The acquisition is expected to close in Q3 2024.
The acquisition will be executed by merging a special purpose company, created under Otsuka America (OAI) for this purpose, into Jnana Therapeutics, with Jnana remaining as the surviving entity.
Following the acquisition, Otsuka aims to enhance its R&D, leveraging Jnana’s next-generation RAPID platform, and expand its global influence. The firm aims to address unmet needs in PKU and autoimmune diseases using Jnana’s technology and small molecule pipeline, which will be added to Otsuka's existing portfolio in the specialty/autoimmune diseases segment.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.